Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
KZ

NASDAQ · KZR

Kezar Life Sciences, Inc.

Healthcare · Biotechnology

$7.29

Up+$0.00 (+0.00%)

Updated Aug 22, 2026, 9:14 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
46.28M
P/E ratio
-0.65
Dividend yield
0.00%
52-week range
$3.53 – $7.55
Volume
616.02K
Avg. volume
176K

Price performance

KZR price history

1M range · 0 trading sessions · Daily adjusted prices

KZR does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest KZR news

The latest Smart Investors Daily articles mentioning KZR.

Stock researchCompany · Overview

KZR research

Overview

Company profile and research snapshot.

Company profile

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
KZR recent ratings
DateFirmRatingTarget
Oct 17, 2025JefferiesHold—
Oct 17, 2025William BlairMarket Perform—
Oct 17, 2025Wells FargoEqual-Weight—
Jul 16, 2025HC Wainwright & Co.Neutral—
Dec 19, 2024Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Dec 3, 2025

Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)

Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation. Profitability This table compares Dyadic International

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By